Corporate News Report – Faes Farma
Faes Farma SA, a long‑standing Spanish pharmaceutical enterprise, has announced a strategic partnership with the Danish company Enzymatica AB to bring its ColdZyme® nasal spray to the Jordanian and Iraqi markets. The collaboration, backed by MedonyX and the regional platform MMDS, will manage product registration, marketing, sales, and distribution. A launch in the first quarter of 2027 is anticipated following regulatory approvals in both countries.
Market Performance
- Trading activity: On Thursday, 22 March 2026, the Faes Farma share (ticker FAE.MC) closed up 3.53 % at EUR 4.71 on major exchanges.
- Trading volume: The last 24 hours saw a turnover of EUR 714.8 k.
- Market capitalisation: The company’s market cap currently stands at EUR 1.5 bn.
- Stock supply: Outstanding shares amount to 311.5 million.
- Trend over the month: The share price has risen 4.08 % since the end of the previous month.
- Technical indicators: The 200‑day simple moving average is EUR 4.72.
- Price range: The 52‑week high was EUR 5.44 (1 July 2026) and the low was EUR 4.32 (15 July 2026).
Strategic Implications
The ColdZyme partnership places Faes Farma in a rapidly expanding region where consumers increasingly seek self‑care solutions for colds and coughs. MMDS’s experience in the Middle East and North Africa (MENA) will facilitate efficient market entry, while the partnership leverages Enzymatica’s local presence and regulatory expertise. The collaboration is expected to broaden Faes Farma’s geographic footprint and enhance revenue streams in emerging markets.
Context within the Sector
Faes Farma’s product portfolio spans prescription medicines, generics, OTC drugs, and health supplements, and the company operates in about 60 countries worldwide. The current partnership complements its strategy of expanding into high‑growth regions and diversifying its sales channels.
Comparative Stock Activity (Last 24 Hours)
| Stock | Ticker | Price Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Pharma Mar | PHM.MC | +1.17 % | EUR 70.70 | EUR 1.2 bn | 20.48 |
| Gestamp Automocion | GEST.MC | +0.68 % | EUR 2.88 | EUR 1.7 bn | 8.82 |
| Linea Directa Aseguradora | LDA.MC | –0.33 % | EUR 1.23 | EUR 1.3 bn | 14.16 |
| Atresmedia De Medios De | A3M.MC | +1.20 % | EUR 5.80 | EUR 1.3 bn | 23.70 |
| Metrovacesa | MVC.MC | +0.58 % | EUR 10.78 | EUR 1.6 bn | 17.41 |
Forward Outlook
Faes Farma’s focus on product expansion in new markets, combined with its robust research and development pipeline, positions the company for sustained growth. Investors should monitor regulatory milestones in Jordan and Iraq, as well as the broader economic conditions in the MENA region, to gauge the partnership’s performance.
